This is very positive news, the letter of intent with AXIM Biotechnologies is now binding and exclusive. AXIM have a massive portfolio of products including the CBD mouthwash and toothpaste required to start the periodontitis trial.
And that is only one of four trials fully funded by Cannvalate. $12 million market capitalization versus $90 million sector average.
